Last update Nov. 25, 2024
Incompatible
We do not have alternatives for Dactinomycin; Actinomycin D.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Dactinomycin; Actinomycin D in other languages or writings:
Dactinomycin; Actinomycin D belongs to these groups or families:
Main tradenames from several countries containing Dactinomycin; Actinomycin D in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | Baja - Low | % |
Molecular weight | 1255 | daltons |
Protein Binding | 5 | % |
pKa | 10.52 | - |
T½ | 36 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Dactinomycin is a highly toxic actinomycin antibiotic with antineoplastic and immunosuppressive properties. It is used in the treatment of Wilms' tumor, gestational trophoblastic tumors, sarcomas such as rhabdomyosarcoma and Ewing's sarcoma and other cancers. It frequently causes potentially serious adverse effects: anemia, pancytopenia, neuropathy, sepsis, liver toxicity, diarrhea... (Recordati 2018). Daily intravenous administration for 5 days.
At the date of the last update we found no published data on its excretion in breast milk.
Its high molecular weight would hinder its excretion in breast milk, but its low binding to plasma proteins could facilitate it.
Its low oral bioavailability makes it difficult for it to pass from ingested breast milk into infant plasma, except in premature infants and the immediate neonatal period when intestinal permeability may be higher.
It is known from pharmacokinetics that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ it is 94%, after 5 T½, 96.9%, after 6 T½, 98.4% and after 7 T½ it is 99%. From 7 T½ the plasma concentrations of the drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period before breastfeeding again.(Anderson 2016).
Taking the longest T½ published as a reference (36 hours), these 5 T½ would correspond to 8 days. Meanwhile, breast milk must be expressed and discarded regularly. This does not allow breastfeeding during treatment.
See below the information of this related product: